To comprehensively characterize the microenvironment of melanoma patients with various stages and subtypes, we used a customized IMC panel of 35 antibodies on baseline tissue samples from 26 melanoma patients treated with anti-PD-1 (Fig. 1a and Supplementary Tables 1–3). This evidence concerns the gene PDCD1 and melanoma.